New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
NCT ID NCT07623642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participate. The goal is to see if the combination shrinks tumors and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Blood and gut clues may flag pancreatic cancer risk early
- Can delivering cancer drug directly to the liver shrink tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates